Roche Nimblegen is offering sequence-capture services through a partnership with SeqWright, a custom genomic and molecular biology service.
SeqWright will provide targeted resequencing services that couple Roche Nimblegen's sequence capture microarray technology with SeqWright's 454 sequencing services on the genome sequencer FLX system.
SeqWright's clients will be able to take advantage of the Nimblegen 2.1M human exome array or custom targeted human resequencing services for regions ranging from 100kbytes up to 30Mbytes.
This service will decrease the time and cost required for targeted and human exome resequencing projects, making these types of studies more readily accessible to researchers.
'We will be able to provide a rapid, cost-effective service that will enable researchers to advance their knowledge of genetic disease factors for basic and clinical research,' said Fei Lu, MD, chief executive officer of SeqWright.
'As a CLIA-certified facility, providing this service will allow applications of targeted resequencing and whole-exome sequencing from disease pathway studies to cancer research,' he added.
Dr Gerd Maass, chief executive officer of Roche Nimblegen, said: 'It will have an impact on personalised healthcare, as we can now quickly target and decipher only the most relevant part of the genome, the human exome, on a single microarray.
'This might provide us with a quicker and more cost-effective way to help us understand common and complex diseases, facilitating their diagnosis and treatment.'
